News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Harvard Bioscience Inc. (HBIO)'s InBreath Bioreactor Highlighted in Article in The Lancet Summarizing the World's First Synthetic Trachea Transplant



11/28/2011 11:20:43 AM

HOLLISTON, Mass., Nov. 28, 2011 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO - News), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, was highlighted in an article published in The Lancet, a leading peer-reviewed medical journal. The article described the world's first synthetic trachea transplant, conducted on June 9, 2011 at the Karolinska University Hospital in Sweden. The procedure involved a stem-cell-seeded bioartificial nanocomposite trachea that was grown in Harvard Bioscience's "InBreath" bioreactor that was produced in its regenerative medicine device business.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES